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Congenital central hypothyroidism (CCH) is a rare condition occurring in 1:20000 to 1:50000 newborns. As TSH plasma levels
are low, CCH is usually not detected by TSH-based neonatal screening for hypothyroidism, and, as a result, diagnosis is often
delayed putting aﬀected children at risk for developmental delay and growth failure. We report on a girl with isolated central
hypothyroidism due to a homozygous one-base pair deletion (T313del) in exon 3 of the TSHβ subunit gene. The molecular
genetic and typical radiologic ﬁndings are discussed, and a systematic diagnostic workup for congenital central hypothyroidism is
proposed. Physicians need to be aware of this rare condition to avoid diagnostic delay and to install prompt replacement therapy.
1.Introduction
Congenital central hypothyroidism (CCH, OMIM#275100)
is an uncommon variant of congenital hypothyroidism with
an incidence of 20.000 to 1:50.000 newborns [1]. CCH
may occur in isolation or in combination with panhy-
popituitarism associated with mutations of genes encoding
transcription factors involved in pituitary development [2].
TheisolatedformofCCHismorediﬃculttodetectclinically
because additional clinical signs such as persistent hypogly-
caemia in case of panhypopituitarism are lacking. Owing
to the eﬃcacy of neonatal screening programs which facil-
itate early diagnosis and prompt initiation of replacement
therapy, the prognosis for children with primary congenital
hypothyroidism has improved signiﬁcantly. Unfortunately,
most screening programs are based on the detection of
elevated TSH levels only to detect children with primary
hypothyroidism [3]. As in CCH TSH levels are low, early
diagnosis is usually missed in TSH-based neonatal screening
putting aﬀected children at risk for mental retardation and
severe growth failure.
2.CaseReport
A female infant, the ﬁrst child to nonconsanguineous Cau-
casian parents, was delivered at 38-week gestation by Cae-
sarean section because of cephalopelvic disproportion. No
signs of peripartum infection were evident. Her birth weight,
length, and head circumference were 2810g (10th–25th
percentile), 50cm (25th–50th percentile), and 35cm (50th–
75th percentile), respectively. She was initially tachypnoeic,
and mild hypoglycaemia (blood glucose 27mg/dL) was
detected on one occasion on day one. Neonatal sepsis was
suspected as C-reactive protein concentrations in blood were
elevated, and chest radiograph was suggestive of pneumonia.
Intravenous piperacillin and netilmicin were begun. Five
days later, blood cultures remained negative, and antibiotic
treatment was discontinued. Screening for hypothyroidism
was considered to be normal as thyrotropin (TSH) was not
elevated (0μU/mL, normal range 0–15μU/mL).
Within the next few days, the patient developed progres-
sive feeding diﬃculties, muscular hypotonia, and somno-
lence.Additionally,jaundicewasobserved(maximumserum2 Case Reports in Pediatrics
bilirubin concentration 15.8mg/dL). On day 19, thyroid
function tests revealed a serum-free thyroxine (fT4) concen-
trationof0.8pmol/L(normalrange12–22pmol/L)whilethe
free L-triiodothyronine (fT3) concentration was 0.4pmol/L
(normal range 3.0–8.4pmol/L, immunological assay). At the
same time, serum TSH was low at 0.05μU/mL (normal
range 0.27–4.2μU/mL); thus, central hypothyroidism was
diagnosed. Her serum thyroglobulin was within the normal
range. Panhypopituitarism was excluded by the ﬁndings
of normal serum levels of ACTH, cortisol, IGF1, IGFBP3,
LH, FSH, cortisol excretion in a 24-hour urine, and blood
glucose proﬁle. An MRI brain scan was normal. Thyroid
ultrasonography revealed a normally located thyroid gland
of appropriate size and shape (0.6, normal 0.3–2.3mL).
Isolatedcentralhypothyroidismwasconﬁrmedfollowingthe
detection of elevated prolactin levels (1141mU/L, normal
range 102–496mU/L). No increase in TSH concentration
was noted following stimulation with thyrotropin-releasing
hormone (TRH) while prolactin was appropriately stimu-
lated with an increase in concentrations noted from 678
to 954mU/L. Bone age (Hernandez/Erasmie Score) was
significantly delayed by 3 months (Figure 1).
Direct sequencing of the entire coding region of the
proposita’s TSHβ gene revealed a homozygous single nucle-
otide deletion of a T at position 313 in exon 3, resulting in
a frame shift mutation with a premature stop at codon 114
(Figure 2). Both clinically unaﬀected parents were hetero-
zygous for the mutation and had normal thyroid hormone
levels.
L-thyroxine replacement therapy was started on day 19
at a starting dose of 50μg/day. Eleven days later, the dose was
reduced to 25μg/day owing to an elevated fT4 serum con-
centration. Following the initiation of therapy, both feeding
problems and lethargy slowly resolved. At ﬁve weeks of age,
the patient was well and was subsequently discharged. Since
discharge, her three monthly fT3, fT4, and prolactin serum
concentrations have been adequately controlled within the
upper normal range, while prolactin concentrations initially
continued to be elevated. Neurological development was
normal at the age of 7 months.
3. Discussion
Isolated CCH is a rare variant of congenital hypothyroidism.
While only very few cases of a mutation in the TRH receptor
gene have been published [4], the majority of cases is
associated with mutations in the TSHβ subunit[5]( O M I M
∗188540). TSH is a 28–30kDa glycoprotein synthesized
and secreted by the anterior pituitary gland. Similar to
other members of the glycoprotein hormone family, it is a
heterotrimeric cystine knot protein consisting of a common
α-subunit and a speciﬁc β-subunit. For the TSHβ gene, nine
diﬀerent mutations have been identiﬁed so far [5, 6], all
leading to isolated TSH deﬁciency. Inheritance is autosomal
recessive. The most frequent TSHβ-subunit mutation is the
1bp deletion in codon 105 (c.T313del, p.C105Vfs∗)i ne x o n
3 as found in our patient [7]. This mutation leads to a
frame shift and a premature stop at codon 114 and predicts
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Figure 1: Radiograph of the baby’s foot at 20 days of chronological
age. Bone age has been classiﬁed as 28th–30th gestational week;
thus,boneageissigniﬁcantlyretarded(accordingtotheHernandez/
Erasmie score).
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Figure 2:Molecular analysisofgenomicDNAidentiﬁedahomozy-
gous one-base pair deletion (T313del) in exon 3 of the TSHβ
subunit gene resulting in a frame shift and a premature stop at
codon 114. The deletion of nucleotide 313 (T) creates a new
restriction site for SnaBI. The allele with the wild-type TSHβ
fragment remained undigested (344bp), whereas the mutant allele
wascutintotwofragmentsof251(asshownintheﬁgure)and93bp
(not shown). Our patient (II1) is homozygous for this mutation,
both parents (I1 and I2) are heterozygous.
the synthesis of a truncated TSHβ subunit [7]. As a con-
sequence, this TSH form is usually not detected by routine
immunological assays and is biologically inactive at the TSH
receptor. A population heterozygote carrier frequency of
c.T313del of less than 1:170 has been estimated for the
German population, and a monophyletic origin is suggestedCase Reports in Pediatrics 3
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Figure 3: Proposed diagnostic workup in CCH for diﬀerentiation between a panhypopituitarism, a TRH-receptor gene mutation and a
TSHβ-gene mutation. Rare other conditions mimicking CCH, such as hypothyroxinemia due to prematurity, primary hypothyroidism with
delayed TSH elevation, and transient CCH must also be ruled out.
by the results of haplotype analyses in carrier families [8].
While its frequency is too low to warrant population wide
neonatal T4 screening, identiﬁcation and genetic counselling
of heterozygous persons in known carrier families are
important [5].
Newborn screening has been designed to detect primary
hypothyroidism. Since in most screening programs attention
is only paid to high TSH levels and fT4 is not measured,
patients with CCH are usually missed. Therefore, diagnosis
and initiation of thyroid hormone substitution may be de-
layed in these cases, resulting in developmental delay [5].
Compared to other cases of CCH published so far with
diagnosis at the age of several months to years, our patient
has been diagnosed early due to distinct clinical signs and
postnatal inpatient treatment [5]. Nevertheless, the correct
diagnosis has been delayed for a few days due to the attribu-
tionofunspeciﬁcsymptomssuchasadynamia,feedingprob-
lems, body temperature instability, and prolonged jaundice
to neonatal sepsis.
Delayed bone age is a common feature of congenital hy-
pothyroidism and seems to correlate with severity of thyroid
dysfunction [9].Pezzutietal.reportedthatinacohortof280
Brazilian children with congenital hypothyroidism 32.1%
had delayed bone age for their chronological age [10]. In this
study, children presenting within the ﬁrst month of life had
signiﬁcantly more abnormal thyroid function and a higher
incidence of retarded bone age in comparison with children
older than 30 days (retarded bone age in 41% versus 21%,
resp.) [10]. These ﬁndings have been conﬁrmed by other
studies such as a longitudinal assessment of L-T4 therapy for
congenital hypothyroidism in Mexico [11], where patients
with delayed bone age at birth had lower T4 and fT4 levels
than patients with normal bone age. Delayed bone age at
birth reﬂects prenatal thyroid dysfunction [12] and is usually
associated with abnormal neuropsychomotor development
within the ﬁrst year of life, irrespective of other variables
related to treatment [9]. Despite signiﬁcantly delayed bone
age at birth, our patient does not show any signs of develop-
mentaldelayuntilnow.However,psychomotordevelopment
will have to be monitored throughout childhood.
To reduce the diagnostic delay in patients with central
hypothyroidism, we recommend the following diagnostic
workup (Figure 3). As CCH is not detected in TSH-based
newborn screening, thyroid hormone levels (fT3, fT4)
should be analyzed immediately if hypothyroidism is clin-
ically suspected. Panhypopituitarism can be diﬀerentiated
from isolated CCH by normal levels of ACTH, cortisol,
IGF1/IGFBP3, LH, FSH, and prolactin. For further differen-
tial diagnosis, a TRH stimulation test can be helpful. A de-
fective TRH receptor will neither stimulate TSH nor pro-
lactin. However, in case of a TSHβ gene mutation, prolactin
levels will be normal or high with further increase after TRH
stimulation proving normal function of the TRH receptor,
but TSH levels remain low. To our knowledge, no genetic
TRH deﬁciency has been reported yet.
4. Conclusion
TSHβ subunit gene mutations may aﬀect the structure of
TSH resulting in a biologically inactive and immunologically
nonreactive protein. Aﬀected infants may be missed in TSH-
based newborn screening programs unless attention is paid
to abnormally low TSH levels. Physicians need to be aware
of this rare condition to avoid diagnostic delay and to install
prompt replacement therapy.
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